Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis.

Niraula S, Ocana A, Ennis M, Goodwin PJ.

Breast Cancer Res Treat. 2012 Jul;134(2):769-81. doi: 10.1007/s10549-012-2073-x. Epub 2012 May 5.

PMID:
22562122
2.

Body mass index and survival after breast cancer diagnosis in Japanese women.

Kawai M, Minami Y, Nishino Y, Fukamachi K, Ohuchi N, Kakugawa Y.

BMC Cancer. 2012 Apr 17;12:149. doi: 10.1186/1471-2407-12-149.

3.

Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status?

Wang N, Wang B, Wang Y, Hu J.

Breast. 2011 Dec;20(6):519-24. doi: 10.1016/j.breast.2011.05.009. Epub 2011 Jun 22.

PMID:
21700456
4.

Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis.

van der Hage JA, Mieog JS, van de Vijver MJ, van de Velde CJ; European Organization for Research and Treatment of Cancer.

Breast Cancer Res. 2007;9(5):R70.

5.

Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.

Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W; Korean Breast Cancer Society.

J Clin Oncol. 2007 Jun 10;25(17):2360-8. Epub 2007 May 21.

PMID:
17515570
6.

Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis.

Protani M, Coory M, Martin JH.

Breast Cancer Res Treat. 2010 Oct;123(3):627-35. doi: 10.1007/s10549-010-0990-0. Epub 2010 Jun 23. Review.

PMID:
20571870
7.

Hip circumference is associated with the risk of premenopausal ER-/PR- breast cancer.

Fagherazzi G, Chabbert-Buffet N, Fabre A, Guillas G, Boutron-Ruault MC, Mesrine S, Clavel-Chapelon F.

Int J Obes (Lond). 2012 Mar;36(3):431-9. doi: 10.1038/ijo.2011.66. Epub 2011 Mar 22.

PMID:
21427693
8.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
9.

Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.

Pujol P, Daures JP, Thezenas S, Guilleux F, Rouanet P, Grenier J.

Cancer. 1998 Aug 15;83(4):698-705.

PMID:
9708933
10.
11.

Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL; National Cancer Institute of Canada Clinical Trials Group MA.17.

J Clin Oncol. 2007 May 20;25(15):2006-11. Epub 2007 Apr 23.

PMID:
17452676
12.
13.

Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group.

Bernoux A, de Cremoux P, Lainé-Bidron C, Martin EC, Asselain B, Magdelénat H.

Breast Cancer Res Treat. 1998 Jun;49(3):219-25.

PMID:
9776505
14.

Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis.

Pierobon M, Frankenfeld CL.

Breast Cancer Res Treat. 2013 Jan;137(1):307-14. doi: 10.1007/s10549-012-2339-3. Epub 2012 Nov 20. Review.

PMID:
23179600
15.

Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.

Yu KD, Liu GY, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM.

Breast. 2007 Jun;16(3):307-15. Epub 2007 Feb 12.

PMID:
17293115
16.

Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer.

Dignam JJ, Wieand K, Johnson KA, Raich P, Anderson SJ, Somkin C, Wickerham DL.

Breast Cancer Res Treat. 2006 Jun;97(3):245-54. Epub 2005 Dec 6.

PMID:
16331345
17.

Central obesity and breast cancer risk: a systematic review.

Harvie M, Hooper L, Howell AH.

Obes Rev. 2003 Aug;4(3):157-73. Review.

PMID:
12916817
18.

Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.

Chen X, Yuan Y, Gu Z, Shen K.

Breast Cancer Res Treat. 2012 Aug;134(3):957-67. doi: 10.1007/s10549-012-1990-z. Epub 2012 Feb 28.

PMID:
22370627
19.

Body weight correlates with mortality in early-stage breast cancer.

Enger SM, Greif JM, Polikoff J, Press M.

Arch Surg. 2004 Sep;139(9):954-58; discussion 958-60.

PMID:
15381612

Supplemental Content

Support Center